Picture of NovoCure logo

NVCR — NovoCure News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Switzerland's Novocure Q3 revenue rises 16%, beats estimates

Switzerland's Novocure Q3 revenue rises 16%, beats estimates


Overview

  • Global oncology company's Q3 revenue rose 16% yr/yr, beating analyst expectations

  • Company raised full-year 2026 revenue and adjusted EBITDA guidance

  • Optune Pax approved in Japan for locally advanced pancreatic cancer


Outlook

  • Novocure raises 2026 net revenue guidance to $736 mln-$743 mln from $710 mln-$725 mln

  • Company lifts 2026 adjusted EBITDA forecast to $24 mln-$34 mln from $0 mln-$15 mln

  • Novocure expects quarterly gross margin in the mid-to-high 70s percent for 2026


Result Drivers

  • ACTIVE PATIENT GROWTH - Co said 19% global growth in active patients drove Q3 revenue increase

  • PRODUCT LAUNCHES IN NEW MARKETS - Co attributed record number of active patients to expanding portfolio and new market launches, per CEO Frank Leonard

  • ONE-TIME CLAIMS APPROVAL BENEFITS - Co recognized $4.4 mln in net revenue from one-time increases in claims approval rates in US and Germany


Company press release: ID:nBw3Trcqha


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$193.40 mln

$182.23 mln (7 Analysts)

Q3 Net Loss

$10.44 mln

Q3 Gross Profit

$148.87 mln

Q3 Operating Income

-$6.17 mln

Q3 Pretax Loss

$7.88 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for NovoCure Limited is $26.00, about 83.5% above its October 28 closing price of $14.17


Reuters Recommended Reads

  • Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

  • Oct 28 - Glaukos Q3 revenue jumps 58% on iDose TR, Epioxa launches, Corneal Health growth

  • Oct 28 - Straumann sees North America stabilising, China demand improving after Q3 beat


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on NovoCure

See all news